Stay updated on Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial page.

Latest updates to the Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial page
- Check2 days agoChange DetectedThe revision tag was updated from v3.5.3 to v3.5.4, indicating a small maintenance update to the page's documentation/versioning. It does not change trial information or user-facing content.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page now displays Revision: v3.5.3, replacing v3.5.2, indicating a new version of the page.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedRevision: v3.5.2 was added and Revision: v3.5.0 was removed.SummaryDifference0.1%

- Check59 days agoChange DetectedAdded the term Hepatocellular carcinoma and a new 'Genetic and Rare Diseases Information Center' resource; updated the site revision from v3.4.3 to v3.5.0.SummaryDifference0.2%

- Check66 days agoChange DetectedPage version updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check88 days agoChange DetectedThe study now lists two locations, including Parkland Health & Hospital System in Dallas, TX; this augments the previously listed single-location site.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Bavituximab in Advanced HCC Clinical Trial page.